Welcome to our dedicated page for Apogee Therapeutics SEC filings (Ticker: APGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apogee Therapeutics, Inc. (APGE) SEC filings page on Stock Titan aggregates the company’s U.S. Securities and Exchange Commission disclosures, providing insight into its status as a Nasdaq-listed, clinical-stage biotechnology issuer. These documents include current reports on Form 8-K, financial statements, equity offering details and other regulatory information that frame Apogee’s development and financing activities in inflammatory and immunology (I&I) therapeutics.
Apogee’s Forms 8-K illustrate how the company reports material events such as quarterly financial results, interim clinical data for programs like APG777 and APG333, and the terms of underwritten public offerings of common stock and pre-funded warrants under an effective shelf registration statement. Selected 8-Ks also summarize outcomes of the annual meeting of stockholders, including director elections, auditor ratification and advisory votes on executive compensation frequency.
Through these filings, investors can review Apogee’s reported research and development and general and administrative expenses, net losses, cash and marketable securities balances, and the impact of capital raises on its operating runway. Offering-related filings describe underwriting agreements, option exercises by underwriters, pre-funded warrant terms and associated legal opinions, all of which help clarify the structure of Apogee’s capital formation.
On Stock Titan, users can access Apogee’s SEC filings alongside AI-powered summaries that explain the key points of lengthy documents such as earnings-related 8-Ks and registration statement updates. This includes highlighting where the company discusses clinical trial timelines, interim data disclosures, and other items relevant to its I&I pipeline. The filings page also surfaces exhibits like press releases and data presentations incorporated into 8-Ks, as well as cover page information confirming that Apogee’s common stock trades on The Nasdaq Global Market under the symbol APGE.
For those monitoring regulatory developments, capital structure changes or disclosure around programs such as APG777, APG279 and APG333, the SEC filings page offers an organized view of Apogee’s official communications with regulators and investors.
Apogee Therapeutics, Inc. received an updated ownership report from several Wellington entities disclosing a sizeable institutional stake in its common stock. The Wellington group reports beneficial ownership of 4,746,585 shares of Apogee common stock, representing 8.66 % of the outstanding class.
The filing states Wellington has no sole voting or dispositive power over these shares. Instead, it reports shared voting power over up to 4,341,936 shares and shared dispositive power over up to 4,746,585 shares, held of record by Wellington investment-advisory clients in the ordinary course of business.
Apogee Therapeutics Chief Medical Officer Carl Dambkowski reported an option exercise and related share sales. On 02/04/2026, he exercised stock options for 4,125 shares of common stock at an exercise price of $22.86 per share.
On the same date, he sold multiple small blocks of Apogee common stock at weighted average prices of $64.88, $65.83, $66.85, $67.88 and $68.94 per share, under a Rule 10b5-1 trading plan adopted on September 22, 2025. After these transactions, he directly held 211,148 shares of common stock and 135,415 derivative securities (stock options) of Apogee Therapeutics.
Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson reported planned stock sales under a Rule 10b5-1 trading plan. On February 2, 2026, she sold 792 shares of common stock at a weighted average price of $65.21, 1,108 shares at $66.15, and 100 shares at $66.89.
The weighted average prices reflect multiple trades in ranges from $64.80 to $65.61 and from $65.84 to $66.75. After these transactions, she directly owned 183,371 shares of Apogee common stock.
The Vanguard Group has disclosed a significant stake in Apogee Therapeutics Inc. As of 12/31/2025, Vanguard reports beneficial ownership of 2,857,824 shares of Apogee common stock, representing 5.21% of the class.
Vanguard reports no sole voting or dispositive power. It has shared voting power over 374,247 shares and shared dispositive power over 2,857,824 shares. The holdings are for clients, who have rights to dividends and sale proceeds, with no single client exceeding 5% of the class.
Vanguard states the shares were acquired and are held in the ordinary course of business, not to change or influence control of Apogee. It also notes an internal realignment effective 01/12/2026, after which certain subsidiaries are expected to report beneficial ownership separately while pursuing the same investment strategies.
Apogee Therapeutics, Inc. insider filing shows a major share sale by an investment fund linked to company directors. Fairmount Healthcare Fund II L.P., managed by Fairmount Funds Management LLC, sold 1,750,000 shares of Apogee common stock on 01/22/2026 at $76.30 per share in an indirect transaction. After this sale, the fund is reported as indirectly holding 298,647 shares of common stock.
The filing also reports that Fairmount Healthcare Fund II L.P. indirectly holds 6,743,321 shares of non-voting common stock, which are convertible into Apogee common stock on a 1-for-1 basis, subject to a beneficial ownership cap of 9.99%, which can be increased to up to 19.99% with 61 days’ notice. Separately, director-affiliated individuals Tomas Kiselak and Peter Harwin are each shown as indirectly holding 51,166 shares of common stock. Fairmount, Kiselak, and Harwin disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
A holder of Apogee Therapeutics (symbol APGE) common stock filed a Form 144 notice to potentially sell 1,750,000 shares through broker Jefferies LLC on or about 01/22/2026 on the NASDAQ. The filing lists an aggregate market value for the planned sale of $133,525,000.00, based on current market prices, compared with 54,833,587 shares of the class outstanding. The shares were originally purchased in the initial public offering on 07/13/2023 from the issuer for cash, with payment dated 07/18/2023.
By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations, and acknowledges that intentional misstatements or omissions would be a federal criminal violation.
Apogee Therapeutics’ major shareholder Fairmount Funds has updated its ownership disclosure after a sizable share sale. Fairmount Healthcare Fund II L.P. and related parties now report beneficial ownership of up to 9.99% of Apogee’s common stock, using both common and non-voting common shares in the calculation and subject to a 9.99% beneficial ownership cap.
The filing shows Fairmount-related entities having voting and dispositive power over 6,031,979 shares of common stock, including shares issuable upon conversion of non-voting common stock. Fund II also holds 6,743,321 shares of non-voting common stock in total, which can convert to common stock within the ownership limits. On January 22, 2026, Fund II sold 1,750,000 shares of common stock in a block trade at $76.30 per share. Directors Peter Harwin and Tomas Kiselak each hold common shares and vested options but disclaim beneficial ownership of the option shares due to arrangements with Fairmount.
Apogee Therapeutics, Inc. Chief Executive Officer and director Michael Thomas Henderson reported open‑market sales of the company’s common stock. On January 14, 2026, he sold shares in multiple transactions at weighted average prices ranging from about $78.16 to $83.84 per share, under a pre‑arranged Rule 10b5-1 trading plan adopted on August 13, 2025. Following these sales, he reported beneficial ownership of 1,192,987 shares of Apogee common stock held directly.
Apogee Therapeutics, Inc. Chief Medical Officer Carl Dambkowski reported several stock transactions in common shares and options. On January 7, 2026, he exercised a stock option for 14,025 shares of common stock at an exercise price of $22.86 per share, then sold shares in multiple trades: 2,954 shares at $77.13, 14,820 shares at $77.90, 826 shares at $79.04, and 100 shares at $80.06. The sales were executed under a Rule 10b5-1 trading plan adopted on September 22, 2025. After these transactions, he beneficially owned 212,523 shares of common stock and 139,540 stock options. The filing also notes that earlier Forms 4 since October 3, 2025 overstated his beneficial ownership by 53,910 shares due to an administrative error, and this report reflects the corrected amount.
APGE insider Carl Dambkowski has filed a Form 144 to sell 35,200 shares of common stock. The planned sale is through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $2,754,400.00, based on 68,320,229 shares outstanding.
The securities to be sold include 26,400 common shares acquired on 01/07/2026 through the exercise of stock options for cash, and 8,800 common shares originally received as restricted stock awards on 09/16/2022.
Over the past three months, 10b5-1 plan sales for Dambkowski included 10,900 common shares sold on 12/04/2025 for $817,528.34, and additional sales on 11/05/2025 of 8,060 shares for $443,860.98 and 2,725 shares for $150,064.66. By signing, the seller represents they are not aware of undisclosed material adverse information about APGE.